<DOC>
	<DOCNO>NCT00925548</DOCNO>
	<brief_summary>EMD Serono decide permanently terminate trial EMR 200038-010 ( STRIDE ) indication breast cancer follow clinical hold investigational new drug application tecemotide ( L-BLP25 ) .</brief_summary>
	<brief_title>STRIDE - STimulating Immune Response In aDvanced brEast Cancer</brief_title>
	<detailed_description>The purpose study determine whether addition experimental mucinous glycoprotein 1 ( MUC1 ) antigen-specific cancer immunotherapy tecemotide ( L-BLP25 ) hormonal treatment effective prolong progression-free survival postmenopausal woman endocrine-sensitive inoperable locally advanced , recurrent metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Postmenopausal woman define protocol Estrogen receptor ( ER ) positive and/or progesterone receptor ( PgR ) positive , histologically cytologically confirm primary carcinoma breast Expressing least one follow five human leukocyte antigen ( HLA ) haplotypes , centrally assess HLA genotyping whole blood : HLAA2 , A3 , A11 , B7 , B35 Locally advance , recurrent , metastatic breast cancer ( Subject must least one lesion locate bone ) Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) , inoperable Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , hepatic , renal function within two week prior initiation therapy , define protocol Other protocoldefined inclusion criterion may apply Disease Status PD either hormonal therapy early breast cancer ( adjuvant therapy ) within 48 month initiation therapy Human epidermal growth factor receptor 2positive ( HER2+ ) breast cancer define protocol Autoimmune disease opinion investigator could compromise safety subject study ( Exception grant wellcontrolled Type I diabetes mellitus ) Recognized immunodeficiency disease , include cellular immunodeficiency , hypogammaglobulinemia dysgammaglobulinemia ; hereditary congenital immunodeficiency Past current history malignant neoplasm breast cancer ( BRCA ) , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix , cancer curatively treat evidence disease least five year Known active Hepatitis B infection carrier state and/or Hepatitis C infection , know Human Immunodeficiency Virus infection , infectious process opinion investigator could compromise subject 's ability mount immune response could expose likelihood and/or severe side effect Pretherapies Receipt immunotherapy ( example [ e.g . ] , interferon ; tumor necrosis factor ; interleukin ; growth factor granulocyte macrophagecolony stimulate factor [ GMCSF ] , granulocytecolony stimulate factor [ GCSF ] , macrophagecolony stimulate factor [ MCSF ] , monoclonal antibody ) , chemotherapy , within four week ( 28 day ) prior randomization . Note : Subjects receive monoclonal antibody image eligible Prior receipt investigational systemic drug ( include offlabel use approve product ) kind systemic treatment ( chemotherapy , immunotherapy ) , exception hormonal therapy ( HT ) give period exceed 4 week ( 28 day ) prior randomization , treatment inoperable , locally advanced , recurrent , metastatic breast cancer Prior radiotherapy site cancer , one site use evaluation tumor response Prior use bisphosphonates concurrent use study treatment allow Physiological Function Central nervous system disease brain metastasis , document compute tomography ( CT ) magnetic resonance imaging ( MRI ) Medical psychiatric condition would interfere ability provide inform consent , communicate side effect , comply protocol requirement Clinically significant cardiac disease , e.g. , cardiac failure New York Heart Association ( NYHA ) class IIIIV ; uncontrolled angina pectoris , uncontrolled arrhythmia , uncontrolled hypertension , myocardial infarction previous six month , confirm electrocardiogram ( ECG ) Splenectomy Standard Criteria Need concurrent treatment nonpermitted therapy ( e.g. , concurrent chemotherapy , radiotherapy , systemic immunosuppressive drug , use herbal medicine botanical formulation intend treat cancer ) protocol therapy . Palliative radiation painful bone lesion allow Participation another clinical study within 30 day prior randomization Known hypersensitivity study drug Known alcohol drug abuse Legal incapacity limit legal capacity Signs symptom suggestive transmissible spongiform encephalopathy , family member suffer ( ed ) . Subject could regard `` vulnerable '' accord International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline ( e.g. , subject 's willingness volunteer clinical trial may unduly influenced expectation , whether justify , benefit associate participation , retaliatory response senior member hierarchy case refusal participate , plus person keep detention ; person nurse home ; subject emergency situation ; homeless person ; nomad ) Any reason , opinion investigator , precludes subject participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase III trial</keyword>
	<keyword>randomize</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>MUC1</keyword>
	<keyword>BLP25</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>postmenopausal breast cancer</keyword>
	<keyword>immunotherapy breast cancer</keyword>
	<keyword>Inoperable locally advanced , recurrent , metastatic endocrine-sensitive Breast Cancer</keyword>
</DOC>